| Q37298652 | (18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease |
| Q92346687 | 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report |
| Q36980376 | 24-hour urine phosphorus excretion and mortality and cardiovascular events |
| Q36199529 | 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis |
| Q49336315 | 25-hydroxyvitamin D Levels was not Associated with Blood Pressure and Arterial Stiffness in Patients with Chronic Kidney Disease |
| Q87364388 | 5(th) Asian PAD Workshop |
| Q90180780 | 99mTc-MIBI SPECT/CT imaging had high sensitivity in accurate localization of parathyroids before parathyroidectomy for patients with secondary hyperparathyroidism |
| Q47103013 | A Dialysis Patient With Hyperphosphatemia, Hyperkalemia, and Azotemia Without an Excessive Intake |
| Q42727652 | A Japanese approach for CKD-MBD |
| Q28552810 | A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone Disease |
| Q48130073 | A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder. |
| Q89108581 | A Pilot Trial to Examine the Changes in Carotid Arterial Inflammation in Renal Transplant Recipients as Assessed by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Computed Tomography (PET/CT) |
| Q35894996 | A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency |
| Q38741675 | A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? |
| Q47102093 | A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism |
| Q59109974 | A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on D |
| Q86978572 | A case report of osteomalacia unmasking primary biliary cirrhosis |
| Q30353115 | A case report of severe calciphylaxis - suggested approach for diagnosis and treatment. |
| Q30313255 | A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine |
| Q30421529 | A computerized treatment algorithm trial to optimize mineral metabolism in ESRD. |
| Q30241974 | A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument |
| Q38737535 | A cross-sectional study measuring vanadium and chromium levels in paediatric patients with CKD. |
| Q36322067 | A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients |
| Q34595154 | A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease |
| Q36249817 | A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria |
| Q37663077 | A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity |
| Q35144464 | A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation |
| Q96111307 | A microRNA Approach to Discriminate Cortical Low Bone Turnover in Renal Osteodystrophy |
| Q42392682 | A neglected issue in dialysis practice: haemodialysate |
| Q33840387 | A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. |
| Q39037214 | A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemo |
| Q86047873 | A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands |
| Q86489985 | A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet |
| Q64933828 | A prospective study of the influence of the skeleton on calcium mass transfer during hemodialysis. |
| Q34229016 | A randomized controlled trial of cholecalciferol supplementation in patients on maintenance hemodialysis |
| Q42060514 | A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. |
| Q44167625 | A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. |
| Q87294172 | A rare manifestation of renal osteodystrophy in a non-compliant child on hemodialysis: Answers |
| Q58707183 | Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: A systematic review and meta-analysis |
| Q37651308 | Abdominal aortic calcification in patients with CKD. |
| Q34759725 | Abdominal aortic calcification is not superior over other vascular calcification in predicting mortality in hemodialysis patients: a retrospective observational study |
| Q91611091 | Abdominal aortic calcification is superior to other arteries calcification in predicting the mortality in peritoneal dialysis patients - a 8 years cohort study |
| Q47441738 | Abdominal aortic calcification score among several vascular calcification scores of plain radiograph is the most reliable predictor of severe coronary artery calcification in dialysis patients. |
| Q41652359 | Abnormalities in biomarkers of mineral and bone metabolism in kidney donors |
| Q57053840 | Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients |
| Q49433201 | Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study |
| Q57218134 | Achievements in CKD-MBD guidelines targets: is there a progress in the implementation practice? |
| Q90288539 | Active Vitamin D in Chronic Kidney Disease: Getting Right Back Where We Started from? |
| Q26853272 | Advances in the use of multimarker panels for renal risk stratification |
| Q39239811 | Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. |
| Q34831607 | Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary--results from a nationwide clinical audit |
| Q37682259 | Alkaline phosphatase and mortality in patients on peritoneal dialysis. |
| Q30234466 | Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. |
| Q35985691 | All-cause mortality in hemodialysis patients with heart valve calcification |
| Q53135279 | Alterations of bone microstructure and strength in end-stage renal failure. |
| Q50050914 | Aluminum overload hampers symptom improvement following parathyroidectomy for secondary hyperparathyroidism |
| Q34158441 | American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis |
| Q36959809 | American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations |
| Q33862914 | An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease. |
| Q42644161 | An integrative review of the methodology and findings regarding dietary adherence in end stage kidney disease |
| Q48063902 | An introduction to CKD-MBD research: restart for the future |
| Q35232708 | An optical method for serum calcium and phosphorus level assessment during hemodialysis |
| Q35507936 | Analysis of Adequacy of 25-Hydroxi vitamin D3 Supplementation in Patients on Hemodialysis and Parathormone, Calcium and Phosphorus Level in the Blood of These Patients |
| Q33608978 | Analysis of Factors Associated with Death in Maintenance Hemodialysis Patients: A Multicenter Study in China |
| Q33890218 | Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients |
| Q36166690 | Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients |
| Q92559498 | Anatomical distribution and number of parathyroid glands, and parathyroid function, after total parathyroidectomy and bilateral cervical thymectomy |
| Q26781300 | Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human Pathology |
| Q49136022 | Approach to cardiovascular disease prevention in patients with chronic kidney disease |
| Q36118217 | Approximation of Corrected Calcium Concentrations in Advanced Chronic Kidney Disease Patients with or without Dialysis Therapy |
| Q36122043 | Arterial Expression of the Calcium-Sensing Receptor Is Maintained by Physiological Pulsation and Protects against Calcification |
| Q58605570 | Assessing the effect of oral activated vitamin D on overall survival in hemodialysis patients: a landmark analysis |
| Q40216321 | Assessing value-based health care delivery for haemodialysis. |
| Q40584816 | Assessment of abdominal aortic calcification at different stages of chronic kidney disease |
| Q34164661 | Assessment of dual-energy X-ray absorptiometry measures of bone health in pediatric chronic kidney disease |
| Q36550028 | Assessment of some cardiovascular risk factors in predialysis chronic kidney disease patients in Southern Nigeria |
| Q36740444 | Assessment of the relationship between serum soluble Klotho and carotid intima-media thickness and left ventricular dysfunction in hemodialysis patients |
| Q50203254 | Association between Extreme Values of Markers of Chronic Kidney Disease: Mineral and Bone Disorder and 5-Year Mortality among Prevalent Hemodialysis Patients |
| Q90727118 | Association between mineral and bone disorder in patients with acute kidney injury following cardiac surgery and adverse outcomes |
| Q37492301 | Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines. |
| Q90002661 | Association between vitamin D levels and mortality in hemodialysis patients: a cohort study |
| Q37010415 | Association of Increased Serum Leptin with Ameliorated Anemia and Malnutrition in Stage 5 Chronic Kidney Disease Patients after Parathyroidectomy |
| Q38685859 | Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function. |
| Q36195181 | Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study |
| Q40266357 | Association of Vitamin D Metabolites With Arterial Function in the Hemodialysis Fistula Maturation Study |
| Q37035402 | Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients. |
| Q37291922 | Association of bone mineral density with biochemical markers of bone turnover in hemodialysis children |
| Q37060129 | Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. |
| Q58795382 | Association of serum mineral parameters with mortality in hemodialysis patients: Data from the Korean end-stage renal disease registry |
| Q35152692 | Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients |
| Q33837711 | Associations between serum-intact parathyroid hormone, serum 25-hydroxyvitamin D, oral vitamin D analogs and metabolic syndrome in peritoneal dialysis patients: a multi-center cross-sectional study |
| Q44250442 | Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level |
| Q55646332 | Associations of dietary macronutrients and micronutrients with the traditional and nontraditional risk factors for cardiovascular disease among hemodialysis patients: A clinical cross-sectional study. |
| Q89376277 | Associations of parathyroid hormone levels and mineral parameters with heart rate variability in patients with end-stage renal disease |
| Q64101849 | Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study |
| Q37339940 | Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients. |
| Q39037212 | Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce? |
| Q33410839 | Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis |
| Q86254957 | Bilateral slipped capital femoral epiphysis in a male adolescent with familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), chronic renal failure, and severe hyperparathyroidism |
| Q55342099 | Bioavailable Testosterone Is Positively Associated With Bone Mineral Density in Male Kidney Transplantation Candidates. |
| Q44823733 | Biochemical markers of mineral bone disorder in South African patients on maintenance haemodialysis |
| Q39254025 | Biomarkers Predicting Bone Turnover in the Setting of CKD. |
| Q47656922 | Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study |
| Q38958627 | Biopsy vs. peripheral computed tomography to assess bone disease in CKD patients on dialysis: differences and similarities. |
| Q54313739 | Bisphophonates in CKD patients with low bone mineral density. |
| Q43692218 | Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. |
| Q28551189 | Bone Canopies in Pediatric Renal Osteodystrophy |
| Q39970839 | Bone Disease after Kidney Transplantation |
| Q90484920 | Bone Mineral Density in Relation to Chronic Kidney Disease After Heart Transplantation: A Retrospective Single-center Study at Skåne University Hospital in Lund 1988-2016 |
| Q39035413 | Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease |
| Q37986588 | Bone and kidney disease: diagnostic and therapeutic implications |
| Q90328403 | Bone biopsy in nephrology practice |
| Q50653568 | Bone density, microarchitecture, and material strength in chronic kidney disease patients at the time of kidney transplantation. |
| Q84912100 | Bone disease after renal transplantation |
| Q26864102 | Bone disease in pediatric chronic kidney disease |
| Q90305128 | Bone fragility in patients with chronic kidney diseases |
| Q35245052 | Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism |
| Q38544166 | Bone kidney interactions |
| Q36067875 | Bone mineral density and fracture risk in older individuals with CKD. |
| Q33835723 | Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis |
| Q58311248 | Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease |
| Q41625862 | Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study. |
| Q38016073 | Bone turnover markers: use in osteoporosis |
| Q84504283 | Bone: osteoporosis therapy--time to consider renal function |
| Q48132419 | CKD complications in kidney-transplanted patients going back to dialysis: impact on patients outcomes |
| Q50022061 | CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'? |
| Q35463999 | CKD-MBD after kidney transplantation |
| Q56355649 | CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy |
| Q37279085 | CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today? |
| Q37359078 | CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis |
| Q37697926 | CKD-mineral and bone disorder: core curriculum 2011. |
| Q47103592 | Calcification Propensity of Serum is Independent of Excretory Renal Function. |
| Q89913858 | Calcification in arteriovenous fistula blood vessels may predict arteriovenous fistula failure: a 5-year follow-up study |
| Q33625695 | Calcification of the aortic arch predicts cardiovascular and all-cause mortality in chronic hemodialysis patients |
| Q43692416 | Calcification of the thoracic aorta determined by three-dimensional computed tomography predicts cardiovascular complications in patients undergoing hemodialysis |
| Q35683826 | Calciphylaxis in a patient affected by rheumatoid arthritis, chronic renal failure, and hyperparathyroidism: a case report |
| Q38175317 | Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism |
| Q33720411 | Calcium Balance in Chronic Kidney Disease |
| Q36234783 | Calcium Mass Balance during Citrate Hemodialysis: A Randomized Controlled Trial Comparing Normal and Low Ionized Calcium Target Ranges |
| Q36910915 | Calcium absorption response to cholecalciferol supplementation in hemodialysis |
| Q33837633 | Calcium balance and negative impact of calcium load in peritoneal dialysis patients |
| Q37878265 | Calcium mass balances in bicarbonate hemodialysis |
| Q26863412 | Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease |
| Q64117955 | Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study |
| Q37787773 | Can we reduce the cardiovascular risk in peritoneal dialysis patients? |
| Q98613237 | Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder |
| Q38308363 | Cardiac imaging in patients with chronic kidney disease |
| Q48164577 | Cardiac valve calcification and risk of cardiovascular or all-cause mortality in dialysis patients: a meta-analysis. |
| Q34572435 | Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. |
| Q27024043 | Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease |
| Q38851470 | Cardiovascular calcification and subcortical bone demineralization in hypertension |
| Q34453236 | Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs |
| Q51736986 | Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. |
| Q26798487 | Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities |
| Q34073740 | Challenges in implementing and maintaining osteoporosis therapy |
| Q35058001 | Changes in DXA and quantitative CT measures of musculoskeletal outcomes following pediatric renal transplantation |
| Q37324775 | Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients |
| Q86553719 | Chapter 3: Management of progression and complications of CKD |
| Q51807865 | Characterization of an Animal Model to Study Risk Factors and New Therapies for the Cardiorenal Syndrome, a Major Health Issue in Our Aging Population. |
| Q33827370 | Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters |
| Q51208856 | Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. |
| Q37570164 | Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). |
| Q38678632 | Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient |
| Q92533944 | Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives |
| Q38635767 | Chronic Kidney Disease-Mineral and Bone Disorder in Asia |
| Q88506406 | Chronic School Absenteeism of Children with Chronic Kidney Disease |
| Q39016039 | Chronic disease management interventions for people with chronic kidney disease in primary care: a systematic review and meta-analysis |
| Q33833414 | Chronic kidney disease and osteoporosis: evaluation and management |
| Q35755179 | Chronic kidney disease and the skeleton |
| Q48323760 | Chronic kidney disease and vitamin D metabolism in human bone marrow-derived MSCs |
| Q37119068 | Chronic kidney disease in children. |
| Q58492145 | Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm S |
| Q85657229 | Chronic kidney disease: Reductions in FGF-23 levels associated with improved outcomes |
| Q34402661 | Chronic kidney disease: mineral and bone disorder in children |
| Q34362759 | Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism |
| Q43960308 | Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism |
| Q36475574 | Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study |
| Q47549937 | Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism |
| Q28079300 | Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis |
| Q30251450 | Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis |
| Q36900943 | Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial |
| Q37916534 | Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease |
| Q39304775 | Circulating markers of bone turnover |
| Q48025173 | Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis. |
| Q36971739 | Clinical Characteristics of Patients with Diabetic Nephropathy on Maintenance Hemodialysis: A Multicenter Cross-sectional Survey in Anhui Province, Eastern China |
| Q37680907 | Clinical Epidemiology of Mineral Bone Disorder Markers in Prevalent Hemodialysis Patients in the Xinjiang Uyghur Autonomous Region in China |
| Q97545305 | Clinical and Healthcare Utilization Outcomes of Parathyroidectomy in CKD and Dialysis Patients |
| Q36432849 | Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. |
| Q47856604 | Clinical characteristics and outcomes of biopsy-proven diabetic nephropathy |
| Q52592826 | Clinical course after parathyroidectomy in adults with end-stage renal disease on maintenance dialysis. |
| Q35809493 | Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study |
| Q56761591 | Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients |
| Q38742857 | Clinical imaging of vascular disease in chronic kidney disease |
| Q30611154 | Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients) |
| Q34828563 | Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis |
| Q34736194 | Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America |
| Q92734235 | Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease |
| Q48032432 | Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. |
| Q37824821 | Clinical practice. Fibroblast growth factor (FGF)23: a new hormone |
| Q34449193 | Clinical utility of vitamin d testing: an evidence-based analysis |
| Q55028819 | Colonic Mucosal Ulceration and Gastrointestinal Bleeding Associated with Sevelamer Crystal Deposition in a Patient with End Stage Renal Disease. |
| Q36193436 | Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients |
| Q96305083 | Community Pharmacy-Based eGFR Screening for Early Detection of CKD in High Risk Patients |
| Q33801022 | Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D |
| Q41542599 | Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials. |
| Q34725113 | Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis |
| Q36994093 | Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients |
| Q30505759 | Comparison of concurrent complications of CKD by 2 risk categorization systems |
| Q35278384 | Comparison of fracture risk prediction among individuals with reduced and normal kidney function. |
| Q92582407 | Comparison of microwave ablation treatments in patients with renal secondary and primary hyperparathyroidism |
| Q37559385 | Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients |
| Q35838611 | Comparison of single CT scan assessment of bone mineral density, vascular calcification and fat mass with standard clinical measurements in renal transplant subjects: the ABC HeART study |
| Q53320924 | Comparison of two different vitamin D supplementation regimens with oral calcifediol in kidney transplant patients. |
| Q36497902 | Con: Phosphate binders in chronic kidney disease |
| Q33837617 | Confounded complexity: vitamin d, parathyroid hormone, and metabolic syndrome in peritoneal dialysis |
| Q36955171 | Conventional hemodialysis is associated with greater bone loss than nocturnal hemodialysis: a retrospective observational study of a convenience cohort |
| Q89947066 | Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis |
| Q48238776 | Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients. |
| Q63866077 | Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis |
| Q37722763 | Coronary artery calcification in chronic kidney disease: An update. |
| Q35598557 | Coronary artery calcifications predict long term cardiovascular events in non diabetic Caucasian hemodialysis patients. |
| Q50531502 | Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study. |
| Q36936601 | Correlates of parathyroid hormone concentration in hemodialysis patients |
| Q50743231 | Correlation between hand/wrist and panoramic radiographs in severe secondary hyperparathyroidism. |
| Q55388960 | Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients. |
| Q40457903 | Cortical bone analysis in a predialysis population: a comparison with a dialysis population. |
| Q33727902 | Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease |
| Q36281399 | Cortical porosity not superior to conventional densitometry in identifying hemodialysis patients with fragility fracture |
| Q57492952 | Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders |
| Q36071962 | Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go. |
| Q35210184 | Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease |
| Q55032559 | Cross-Sectional Assessment of Achievement of Therapeutic Goals in a Canadian Multidisciplinary Clinic for Patients With Advanced Chronic Kidney Disease. |
| Q50952523 | Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. |
| Q38059124 | Current trends in surgery for renal hyperparathyroidism (RHPT)--an international survey |
| Q37622161 | Cystatin C is Better than Serum Creatinine for Estimating Glomerular Filtration Rate to Detect Osteopenia in Chronic Kidney Disease Patients |
| Q35917442 | Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol |
| Q38714295 | Declining Rates of Hip Fracture in End-stage Renal Disease: Analysis from the 2003-2011 Nationwide Inpatient Sample |
| Q35983513 | Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. |
| Q38339007 | Defective skeletal mineralization in pediatric CKD. |
| Q37256525 | Delayed progression to dialysis with early and intensive management of predialysis chronic kidney disease: a case-based approach |
| Q39394204 | Dental implant treatment for renal failure patients on dialysis: a clinical guideline |
| Q34241519 | Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. |
| Q37508493 | Determinants of bone mineral density in patients on haemodialysis or peritoneal dialysis--a cross-sectional, longitudinal study |
| Q40501573 | Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients |
| Q36547092 | Development and evaluation of continuing education course in renal nutrition |
| Q37673251 | Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients |
| Q36645688 | Diagnosis of low bone mass in CKD-5D patients |
| Q64958368 | Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). |
| Q36941547 | Diagnostic Accuracy Study of Intraoperative and Perioperative Serum Intact PTH Level for Successful Parathyroidectomy in 501 Secondary Hyperparathyroidism Patients |
| Q51244901 | Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. |
| Q41863686 | Diagnostic Workup for Disorders of Bone and Mineral Metabolism in Patients with Chronic Kidney Disease in the Era of KDIGO Guidelines |
| Q98195443 | Diagnostic performance of ultrasonography, dual-phase 99mTc-MIBI scintigraphy, early and delayed 99mTc-MIBI SPECT/CT in preoperative parathyroid gland localization in secondary hyperparathyroidism |
| Q36810506 | Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients |
| Q83729408 | Dialysis: Is the road to survival paved with good mineral management? |
| Q92043628 | Dietary intake as a predictor for all-cause mortality in hemodialysis subjects (NUGE-HD study) |
| Q85251793 | Dietary phosphorus intake and distribution in Chinese peritoneal dialysis patients with and without hyperphosphatemia |
| Q36073058 | Diets for patients with chronic kidney disease, should we reconsider? |
| Q94410108 | Differences in phosphatemia and frequency of consumption of dietary sources of phosphorus in hemodialysis patients in southern and northern Brazil |
| Q36267767 | Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients |
| Q37912038 | Diseases of the parathyroid gland in chronic kidney disease. |
| Q33570848 | Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy |
| Q26786273 | Do kidney stone formers have a kidney disease? |
| Q31033697 | Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels? |
| Q26830747 | Does PTH offer additive value to ALP measurement in assessing CKD-MBD? |
| Q41241653 | Dosage and toxicity of antirheumatic drugs in renal insufficiency |
| Q33840398 | Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study |
| Q38985548 | Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms |
| Q64071286 | Dual Roles of the Mineral Metabolism Disorders Biomarkers in Prevalent Hemodilysis Patients: In Renal Bone Disease and in Vascular Calcification |
| Q35824855 | Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design |
| Q43091596 | Dysphoria induced in dialysis providers by secondary hyperparathyroidism |
| Q85961108 | EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice |
| Q35898342 | Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease |
| Q35692418 | Early skeletal and biochemical alterations in pediatric chronic kidney disease |
| Q42678184 | Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy |
| Q37522761 | Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: rationale and design of the EARNEST study |
| Q55059919 | Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. |
| Q37267792 | Effect of chronic kidney disease on the healing of titanium implants |
| Q34704916 | Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends |
| Q34336027 | Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study |
| Q91834846 | Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study |
| Q48226016 | Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency |
| Q50021375 | Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study |
| Q37135110 | Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease |
| Q33914268 | Effect of niacin on FGF23 concentration in chronic kidney disease |
| Q84834712 | Effect of nutritional vitamin D preparations on parathyroid hormone in patients with chronic kidney disease |
| Q36109164 | Effect of risedronate on bone in renal transplant recipients |
| Q44186583 | Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study |
| Q36121519 | Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis |
| Q28484646 | Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis |
| Q46279772 | Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia |
| Q90391699 | Effects of Social Disparities on Management and Surgical Outcomes for Patients with Secondary Hyperparathyroidism |
| Q47808500 | Effects of Vitamin D2 Supplementation on Vitamin D3 Metabolism in Health and CKD. |
| Q34629853 | Effects of a renal rehabilitation exercise program in patients with CKD: a randomized, controlled trial |
| Q36980309 | Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients |
| Q28535084 | Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin? |
| Q36293813 | Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. |
| Q35853288 | Effects of frequent hemodialysis on measures of CKD mineral and bone disorder |
| Q37578427 | Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study |
| Q39237776 | Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease |
| Q51167379 | Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease. |
| Q36957341 | Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes |
| Q53662466 | Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis. |
| Q57218116 | Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study |
| Q57214044 | Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients |
| Q36255981 | Effects of the Administration of 25(OH) Vitamin D3 in an Experimental Model of Chronic Kidney Disease in Animals Null for 1-Alpha-Hydroxylase |
| Q38228157 | Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review. |
| Q96132965 | Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis |
| Q92206362 | Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial |
| Q35677318 | Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis |
| Q35735678 | Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency |
| Q87748892 | Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis |
| Q88930749 | Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia |
| Q33715510 | Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease |
| Q91817150 | Efficacy of Ultrasound-guided Radiofrequency Ablation of Parathyroid Hyperplasia: Single Session vs. Two-Session for Effect on Hypocalcemia |
| Q37638757 | Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study |
| Q55401202 | Efficacy of microwave ablation for severe secondary hyperparathyroidism in subjects undergoing hemodialysis. |
| Q43541732 | Efficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy |
| Q38684913 | Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism |
| Q37613856 | Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia |
| Q47099897 | Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease |
| Q34428293 | Elevated cardiac markers in chronic kidney disease as a consequence of hyperphosphatemia-induced cardiac myocyte injury |
| Q57494590 | End-Stage Renal Disease Impairs the Multidirectional Movements of the Common Carotid Artery: Assessment Using Dimensional Speckle-Tracking Carotid Strain Ultrasonography |
| Q99241006 | Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease |
| Q36944692 | Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial |
| Q44125749 | Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. |
| Q91596114 | Ergocalciferol improves endothelial vasodilatory and vasoconstrictor function in an in vivo model of mild uraemia |
| Q36157949 | Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients |
| Q34171858 | Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state |
| Q37065614 | Estimated GFR and fracture risk: a population-based study |
| Q40112709 | Estimates of health utility scores in chronic kidney disease |
| Q36358702 | Estimating the financial cost of chronic kidney disease to the NHS in England |
| Q91976651 | Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients |
| Q58765282 | Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal |
| Q33602332 | Evaluating bone quality in patients with chronic kidney disease |
| Q48316515 | Evaluation of a New Fully Automated Assay for Plasma Intact FGF23. |
| Q99556006 | Evaluation of a Pharmacist-Dietician-Led Patient-Centered Approach to Managing CKD-MBD: A Mixed-Method Study |
| Q45722028 | Evaluation of a TPTX model induced by ischemia |
| Q34213692 | Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability |
| Q39225909 | Evaluation of fracture risk in chronic kidney disease. |
| Q90408675 | Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism |
| Q88421208 | Evidence basis for integrated management of mineral metabolism in patients with end-stage renal disease |
| Q99241069 | Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait? |
| Q37340239 | Evidence-based cardiology in hemodialysis patients |
| Q47095498 | Evolve trial |
| Q38997705 | Examining the Proportion of Dietary Phosphorus From Plants, Animals, and Food Additives Excreted in Urine |
| Q89365606 | Extracellular Fluid Excess Is Significantly Associated With Coronary Artery Calcification in Patients With Chronic Kidney Disease |
| Q39387561 | FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study |
| Q43641211 | FGF23 concentrations measured using "intact" assays similar but not interchangeable |
| Q35065731 | FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice |
| Q64063902 | FGF23, Biomarker or Target? |
| Q37045918 | Fabry's Disease: Case Series and Review of Literature |
| Q39034880 | Facility Practice Variation to Help Understand the Effects of Public Policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS). |
| Q36183258 | Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis |
| Q46718053 | Factors affecting postoperative activities of daily living in patients with osteoporotic vertebral collapse with neurological deficits. |
| Q91740105 | Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study |
| Q36104846 | Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. |
| Q35106352 | Ferric citrate |
| Q35577405 | Ferric citrate (auryxia) for the treatment of hyperphosphatemia |
| Q37621547 | Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. |
| Q33873450 | Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. |
| Q30544587 | Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism |
| Q34281341 | Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease |
| Q84403337 | Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis |
| Q34320155 | Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial |
| Q40268402 | Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease |
| Q36759150 | Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study |
| Q34857539 | Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis |
| Q49587355 | Formulary Drug Review: Etelcalcetide |
| Q36204295 | Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database |
| Q37929014 | Fracture risk assessment in patients with chronic kidney disease |
| Q64947171 | Fracture risk in chronic kidney disease: A Korean population-based cohort study. |
| Q46275115 | Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis. |
| Q44114622 | Fractures in Patients with CKD: Time for Action |
| Q59051207 | Fragility Fractures in Chronic Kidney Disease: Assessment and Pharmacologic Management |
| Q36469117 | Frequency of bone mineral density testing in adult kidney transplant recipients from Ontario, Canada: a population-based cohort study |
| Q39946556 | Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy |
| Q26750002 | Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review |
| Q27022356 | Gaps between Global Guidelines and Local Practices in CKD-MBD |
| Q41510628 | Gastrointestinal complications induced by sevelamer crystals |
| Q36207167 | Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis |
| Q39705072 | Geovariation in Fracture Risk among Patients Receiving Hemodialysis |
| Q55016620 | Getting Out of the Phosphate Bind: Trials to Guide Treatment Targets. |
| Q58781019 | Growth and Nutrition in Pediatric Chronic Kidney Disease |
| Q39102625 | Habitual dietary phosphorus intake and urinary excretion in chronic kidney disease patients: a 3-day observational study. |
| Q36088902 | Haemodialysate: long neglected, difficult to optimize, may modify hard outcomes |
| Q35124228 | Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? |
| Q38381204 | Health care prioritization: a clinician's duty. |
| Q35804097 | Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis |
| Q34790266 | Healthcare use and costs before and after parathyroidectomy in patients on dialysis |
| Q38826590 | Heart failure and kidney dysfunction: epidemiology, mechanisms and management |
| Q26824149 | Heart failure in patients with chronic kidney disease: a systematic integrative review |
| Q36965339 | Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients |
| Q90208268 | Hidden Hypocalcemia as a Risk Factor for Cardiovascular Events and All-Cause Mortality among Patients Undergoing Incident Hemodialysis |
| Q33776200 | High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, A pre-post intervention clinical trial |
| Q36290116 | High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis |
| Q36104814 | High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis |
| Q37607448 | High Serum Alkaline Phosphatase, Hypercalcaemia, Race, and Mortality in South African Maintenance Haemodialysis Patients. |
| Q51782027 | High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study. |
| Q34971759 | High peritoneal KT/V and peritonitis rates are associated with peritoneal calcification |
| Q47695950 | High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients |
| Q37542005 | High rates of death and hospitalization follow bone fracture among hemodialysis patients |
| Q47843993 | High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications |
| Q35747238 | High-intensity focussed ultrasound (HIFU) treatment in uraemic secondary hyperparathyroidism. |
| Q59792025 | Higher Proportion of Non-1-84 PTH Fragments in Peritoneal Dialysis Patients Compared to Hemodialysis Patients Using Solutions Containing 1.75 mmol/l Calcium |
| Q89834558 | How We Manage Bone Marrow Edema-An Interdisciplinary Approach |
| Q61451569 | How radical is total parathyroidectomy in patients with renal hyperparathyroidism? |
| Q38970634 | How the reference values for serum parathyroid hormone concentration are (or should be) established? |
| Q28068593 | Hyperparathyroidism of Renal Disease |
| Q38102603 | Hyperphosphataemia: treatment options |
| Q26743842 | Hyperphosphatemia Management in Patients with Chronic Kidney Disease |
| Q26830013 | Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence |
| Q41058577 | Hypoalbuminemia at admission predicts the development of acute kidney injury in hospitalized patients: A retrospective cohort study. |
| Q90666856 | Hypocalcemia-based prediction of hungry bone syndrome after parathyroidectomy in hemodialysis patients with refractory secondary hyperparathyroidism |
| Q33770086 | Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial |
| Q36195418 | Impact of Dialysate Calcium Concentration on Clinical Outcomes in Incident Hemodialysis Patients |
| Q42177717 | Impact of Different Levels of iPTH on All-Cause Mortality in Dialysis Patients with Secondary Hyperparathyroidism after Parathyroidectomy. |
| Q92637028 | Impact of Percent Body Fat on All-Cause Mortality among Adequate Dialysis Patients with and without Insulin Resistance: A Multi-Center Prospective Cohort Study |
| Q90288544 | Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era? |
| Q92302556 | Impact of Subtotal Parathyroidectomy on Clinical Parameters and Quality of Life in Hemodialysis Patients with Secondary Hyperparathyroidism |
| Q37201569 | Impact of age on survival predictability of bone turnover markers in hemodialysis patients |
| Q34459406 | Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study |
| Q40090142 | Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in Japan. |
| Q35051572 | Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era. |
| Q41496586 | Impact of post-dialysis calcium level on ex vivo rat aortic wall calcification |
| Q57807457 | Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study |
| Q47107653 | Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - A systematic review and meta-analysis |
| Q37528772 | Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism. |
| Q35032235 | Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells |
| Q36668070 | Impaired vitamin D metabolism in CKD |
| Q41460824 | Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. |
| Q34036570 | Improvements in renal replacement therapy practice patterns in estonia |
| Q58720808 | Inadequate dietary energy intake associates with higher prevalence of metabolic syndrome in different groups of hemodialysis patients: a clinical observational study in multiple dialysis centers |
| Q44635041 | Incidence and risk factors for hip fractures in dialysis patients |
| Q58747343 | Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms |
| Q91893228 | Increased Risk of Infection-Related and All-Cause Death in Hypercalcemic Patients Receiving Hemodialysis: The Q-Cohort Study |
| Q51282990 | Increased risk of hip fracture among Japanese hemodialysis patients. |
| Q35392994 | Increased risks of mortality and atherosclerotic complications in incident hemodialysis patients subsequently with bone fractures: a nationwide case-matched cohort study. |
| Q46659969 | Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis |
| Q33622180 | Increasing use of vitamin D supplementation in the chronic renal insufficiency cohort study |
| Q35180369 | Indian commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorders |
| Q33571316 | Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation |
| Q41190048 | Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. |
| Q92444112 | Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites |
| Q35733003 | Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease |
| Q89256650 | Initial surgical results of 500 Parathyroidectomies for Hyperparathyroidism related to chronic kidney disease - mineral and bone disorder |
| Q38671509 | Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. |
| Q91910088 | Insulin Resistance and Cardiovascular Risks in Different Groups of Hemodialysis Patients: A Multicenter Study |
| Q47275858 | Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis |
| Q54306096 | Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care. |
| Q35985866 | Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients |
| Q62271292 | Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function |
| Q98178842 | International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study |
| Q30940152 | International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data |
| Q35051203 | Interpreting vitamin D assay results: proceed with caution |
| Q91588283 | Intestinal phosphate absorption: The paracellular pathway predominates? |
| Q87393505 | Introduction: The case for updating and context |
| Q41825674 | Introduction: expanding concepts of chronic kidney disease-mineral and bone disorder (CKD-MBD) |
| Q37069943 | Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients |
| Q39440902 | Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? |
| Q35207839 | Iron-based phosphate binders: do they offer advantages over currently available phosphate binders? |
| Q36612812 | Is abdominal aortic calcification score a cost-effective screening tool to predict atherosclerotic carotid plaque and cardiac valvular calcification in patients with end-stage renal disease? |
| Q35030657 | Is coronary artery calcification associated with vertebral bone density in nondialyzed chronic kidney disease patients? |
| Q87871599 | Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients? |
| Q34366087 | Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? |
| Q37052004 | Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. |
| Q36157050 | Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism |
| Q38718548 | Kidney disease in children: latest advances and remaining challenges |
| Q34659157 | Kidney disease: improving global outcomes |
| Q35891595 | Kinetics of serum 25-hydroxyvitamin D in haemodialysis patients treated with monthly oral cholecalciferol |
| Q57111719 | Krait envenomation in Thailand |
| Q34035017 | Laboratory test surveillance following acute kidney injury |
| Q64231913 | Lack of Awareness of Dietary Sources of Phosphorus Is a Clinical Concern |
| Q27013882 | Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence |
| Q57216815 | Lanthanum carbonate stimulates bone formation in a rat model of renal insufficiency with low bone turnover |
| Q26773120 | Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment |
| Q41146384 | Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease |
| Q34365864 | Limited referral to nephrologists from a tertiary geriatric outpatient clinic despite a high prevalence of chronic kidney disease and anaemia |
| Q33574532 | Lipid, blood pressure and kidney update 2013. |
| Q35479821 | Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal dialysis: a meta-analysis |
| Q47133604 | Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study). |
| Q51742033 | Long-term clinical parameters after switching to nocturnal haemodialysis: a Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration. |
| Q44820678 | Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis |
| Q36486640 | Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). |
| Q55617404 | Longitudinal Assessment of PTH in Community-Dwelling Older Women-Elevations Are Not Associated With Mortality. |
| Q87945558 | Longitudinal assessment of bone quality in pediatric patients with chronic kidney disease in relation to treatment modality |
| Q55109311 | Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism. |
| Q36127512 | Low Potassium Dialysate as a Protective Factor of Sudden Cardiac Death in Hemodialysis Patients with Hyperkalemia |
| Q38283483 | Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysis |
| Q37250213 | Low cardiac index and stroke volume on admission are associated with poor outcome in critically ill burn patients: a retrospective cohort study |
| Q41042187 | Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients |
| Q47789778 | Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients |
| Q42426578 | Low-protein diets for chronic kidney disease patients: the Italian experience. |
| Q38978699 | Low-trauma fractures without osteoporosis |
| Q38473932 | Magnesium and cardiovascular complications of chronic kidney disease |
| Q64896692 | Management Practice, and Adherence and Its Contributing Factors among Patients with Chronic Kidney Disease at Tikur Anbessa Specialized Hospital: A Hospital Based Cross-Sectional Study. |
| Q53501050 | Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. |
| Q96155679 | Management of Multi Organ Dysfunction in Neonatal Encephalopathy |
| Q26781361 | Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations |
| Q35608435 | Management of hyperphosphataemia in chronic kidney disease-challenges and solutions |
| Q62618708 | Management of mineral metabolism in haemodialysis patients: need for new strategies |
| Q61044687 | Management of mineral metabolism in hemodialysis patients: discrepancy between interventions and perceived causes of failure |
| Q39023147 | Management of phosphorus load in CKD patients. |
| Q40889096 | Management of secondary hyperparathyroidism-current impact of parathyroidectomy |
| Q38775426 | Management of secondary hyperparathyroidism: how and why? |
| Q33676534 | Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study. |
| Q58866156 | Management practice, and adherence and its contributing factors among patients with chronic kidney disease at Tikur Anbessa Specialized Hospital: A hospital-based cross-sectional study |
| Q50024790 | Managing hyperparathyroidism in hemodialysis: role of etelcalcetide |
| Q35058295 | Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease |
| Q34582124 | Markers of increased cardiovascular risk in patients with chronic kidney disease. |
| Q55463750 | Matrix metalloproteinase-1 and -2 as markers of mineral bone disease in chronic kidney disease patients. |
| Q35863052 | Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study |
| Q90319101 | Measurement of serum irisin in the different stages of chronic kidney disease |
| Q34405366 | Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. |
| Q26798296 | Mechanism and Treatment Strategy of Osteoporosis after Transplantation |
| Q37902504 | Mechanisms and treatment of extraosseous calcification in chronic kidney disease |
| Q30409314 | Medial vascular calcification revisited: review and perspectives |
| Q43233976 | Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease |
| Q37195397 | Metabolic bone diseases in kidney transplant recipients |
| Q36686979 | Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry |
| Q35773561 | Micro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantation |
| Q92524312 | Mid-arm circumference, body fat, nutritional and inflammatory biomarkers, blood glucose, dialysis adequacy influence all-cause mortality in hemodialysis patients: A prospective cohort study |
| Q36123640 | Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014 |
| Q35639150 | Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? |
| Q37291977 | Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease |
| Q42863013 | Mineral and bone disease in black african hemodialysis patients. |
| Q26771398 | Mineral and bone disorder after kidney transplantation |
| Q53817856 | Mineral and bone disorder and outcomes in hemodialysis patients: results from the DOPPS. |
| Q34418538 | Mineral and bone disorder in Chinese dialysis patients: a multicenter study |
| Q37938689 | Mineral and bone disorders in children with chronic kidney disease |
| Q42727533 | Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation |
| Q38452732 | Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities |
| Q38765338 | Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis |
| Q33580238 | Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models |
| Q36994038 | Mineral metabolic abnormalities and mortality in dialysis patients |
| Q37871341 | Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers |
| Q36509327 | Mineral metabolites and CKD progression in African Americans |
| Q30234751 | Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. |
| Q33625482 | Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients |
| Q33873427 | Multidisciplinary care for poor patients with chronic kidney disease in Mexico |
| Q94465754 | Multiple Measures of Mineral Metabolism Were Associated With Renal Function in Chinese Centenarians: A Cross-Sectional Study |
| Q55509850 | Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism. |
| Q49695446 | NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. |
| Q92432667 | NUTRITIONAL OR ACTIVE VITAMIN D FOR THE CORRECTION OF MINERAL METABOLISM ABNORMALITIES IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS? |
| Q35803618 | Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis |
| Q88805549 | Neutrophil Gelatinase-Associated Lipocalin as a Promising Novel Biomarker for Early Detection of Kidney Injury |
| Q53137940 | Neutrophil gelatinase-associated lipocalin reflects the severity of anemia without iron deficiency and secondary hyperparathyroidism in hemodialysis patients. |
| Q37195458 | New options for the management of hyperparathyroidism after renal transplantation |
| Q92104995 | New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology |
| Q38213502 | Next-generation phosphate binders: focus on iron-based binders |
| Q27006968 | Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients |
| Q38842982 | Nicotinamide and phosphate homeostasis in chronic kidney disease |
| Q59808997 | Non-Hepatic Alkaline Phosphatase, hs-CRP and Progression of Vertebral Fracture in Patients with Rheumatoid Arthritis: A Population-Based Longitudinal Study |
| Q53397196 | Noninvasive Imaging of Bone Microarchitecture in Patients Receiving Renal Transplant: Can it Replace Histology? |
| Q42092498 | Noninvasive assessment of bone health in Indian patients with chronic kidney disease |
| Q37921598 | Noninvasive imaging for assessment of calcification in chronic kidney disease |
| Q47570607 | Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm. |
| Q86042235 | Normocalcemic primary hyperparathyroidism |
| Q50917530 | Not only for the risk of bone fracture. |
| Q36225208 | Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease |
| Q93044584 | Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease |
| Q50051044 | Novel treatment strategies for chronic kidney disease: insights from the animal kingdom. |
| Q36280326 | Npt2b deletion attenuates hyperphosphatemia associated with CKD. |
| Q36890341 | Nutrition in Cardioskeletal Health. |
| Q37564731 | Nutrition prescription to achieve positive outcomes in chronic kidney disease: a systematic review |
| Q35278465 | Nutritional vitamin D supplementation in dialysis: a randomized trial |
| Q30423049 | Observational studies versus randomized controlled trials: avenues to causal inference in nephrology |
| Q49166621 | Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes |
| Q33606649 | Opportunities for Engaging Patients in Kidney Research |
| Q95816357 | Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease |
| Q34939232 | Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease |
| Q44125599 | Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism |
| Q41937202 | Oral postdialysis cholecalciferol supplementation in patients on maintenance hemodialysis: a dose-response approach. |
| Q38505468 | Osteoclastomas ('brown tumours') and spinal cord compression: a review |
| Q35182281 | Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients |
| Q92246457 | Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase |
| Q30235173 | Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. |
| Q39014553 | Osteoporosis in patients with diabetes after kidney transplantation |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q97530990 | Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study |
| Q38206487 | Osteoprotegerin and kidney disease |
| Q38978628 | Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients |
| Q40954425 | Outcome after prenatal diagnosis of congenital anomalies of the kidney and urinary tract |
| Q39017618 | Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock |
| Q30430904 | Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. |
| Q50696787 | Overweight and Abdominal Obesity Association with All-Cause and Cardiovascular Mortality in the Elderly Aged 80 and Over: A Cohort Study. |
| Q43221570 | Parathyroid gland: cinacalcet-can it control hypercalcemia? |
| Q91625183 | Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status |
| Q34989448 | Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. |
| Q35119033 | Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice |
| Q35612518 | Parathyroidectomy Is Associated with Reduced Mortality in Hemodialysis Patients with Secondary Hyperparathyroidism |
| Q37065618 | Parathyroidectomy and heart rate variability in patients with stage 5 CKD. |
| Q41198044 | Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. |
| Q83223028 | Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism |
| Q42371167 | Parathyroidectomy or Calcimimetic to Treat Hypercalcemia after Kidney Transplantation? |
| Q64232656 | Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis |
| Q35920190 | Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study |
| Q49908584 | Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease |
| Q36833143 | Patient education for phosphorus management in chronic kidney disease |
| Q34669852 | Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. |
| Q44434530 | Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH. |
| Q38824573 | Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease |
| Q34213752 | Pharmacology, efficacy and safety of oral phosphate binders |
| Q52733199 | Phenotyping of Acute Kidney Injury: Beyond Serum Creatinine. |
| Q39355201 | Phosphate Additive Avoidance in Chronic Kidney Disease |
| Q36141100 | Phosphate Binding with Sevelamer Preserves Mechanical Competence of Bone Despite Acidosis in Advanced Experimental Renal Insufficiency. |
| Q42746251 | Phosphate Metabolism in CKD Stages 3-5: Dietary and Pharmacological Control |
| Q37984042 | Phosphate additives in food--a health risk |
| Q38594874 | Phosphate and FGF-23 homeostasis after kidney transplantation |
| Q33566596 | Phosphate and cardiovascular disease |
| Q57213546 | Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) |
| Q39155279 | Phosphate binders in patients with chronic kidney disease. |
| Q38079128 | Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children |
| Q27025339 | Phosphate control in dialysis |
| Q26853372 | Phosphate control in end-stage renal disease: barriers and opportunities |
| Q33877167 | Phosphate metabolism modulation in chronic kidney disease: when, how and to what extent? |
| Q37492019 | Phosphate: an old bone molecule but new cardiovascular risk factor |
| Q55524819 | Phosphorus Balance in Adolescent Girls and the Effect of Supplemental Dietary Calcium. |
| Q85316417 | Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD |
| Q36349451 | Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake |
| Q28535870 | Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study |
| Q38784143 | Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis |
| Q92432140 | Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study |
| Q39328170 | Positioning novel biologicals in CKD-mineral and bone disorders. |
| Q97527815 | Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients |
| Q35007369 | Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis |
| Q26777613 | Pre-treatment considerations in childhood hypertension due to chronic kidney disease |
| Q37204047 | Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide |
| Q42025679 | Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders |
| Q33704263 | Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome |
| Q64055567 | Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries |
| Q34858005 | Prescribed dietary phosphate restriction and survival among hemodialysis patients |
| Q36199558 | Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study |
| Q49825558 | Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney Disease |
| Q27022366 | Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease |
| Q37015581 | Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India |
| Q33944765 | Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen |
| Q36612883 | Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria |
| Q42246883 | Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. |
| Q37672557 | Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes |
| Q87373862 | Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005-2008: is treatment with bisphosphonates an option? |
| Q37670530 | Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey |
| Q90712233 | Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest |
| Q37198454 | Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population |
| Q35669317 | Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. |
| Q37275615 | Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality |
| Q90598888 | Protective Role of Vitamin D in Renal Tubulopathies |
| Q37271191 | Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease. |
| Q41295481 | Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes |
| Q35579142 | Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial |
| Q64097494 | Quality of life and its predictors among patients with chronic kidney disease: A hospital-based cross sectional study |
| Q36037470 | Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis |
| Q55265825 | Racial Variations in the Markers of Mineral Bone Disorders in CKD Patients in South Africa. |
| Q35860700 | Racial differences in markers of mineral metabolism in advanced chronic kidney disease |
| Q36098360 | Racial differences in parathyroid hormone levels in CKD. |
| Q39447041 | Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. |
| Q37069993 | Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States |
| Q36104887 | Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. |
| Q34680658 | Re-evaluating the predictive roles of metabolic complications and clinical outcome according to eGFR levels--a four-years prospective cohort study in Taiwan |
| Q38623327 | Receipt of Nephrology Care and Clinical Outcomes Among Veterans With Advanced CKD. |
| Q26849298 | Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease |
| Q37248630 | Recent advances in the noninvasive diagnosis of renal osteodystrophy |
| Q34828835 | Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study |
| Q37391528 | Recombinant PTH associated with hypercalcaemia and renal failure |
| Q49473827 | Reduced kidney function is associated with BMD, bone loss and markers of mineral homeostasis in older women: a 10-year longitudinal study |
| Q36825820 | Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model |
| Q42371213 | Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. |
| Q38731743 | Reexamining the Phosphorus-Protein Dilemma: Does Phosphorus Restriction Compromise Protein Status? |
| Q64082483 | Refractory secondary hyperparathyroidism in waiting list for parathyroidectomy: who we should operate first in a quaternary hospital in Brazil regarding survival |
| Q36815481 | Regional citrate anticoagulation in hemodialysis: an observational study of safety, efficacy, and effect on calcium balance during routine care |
| Q40747969 | Relationship between abdominal aortic and coronary artery calcification as detected by computed tomography in chronic kidney disease patients |
| Q41491440 | Relationship between mild-to-moderate chronic kidney disease and decreased bone mineral density in Chinese adult population |
| Q87311239 | Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease |
| Q36746618 | Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study |
| Q35242517 | Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study |
| Q39301592 | Renal Osteodystrophy or Kidney-Induced Osteoporosis? |
| Q39280064 | Renal Osteodystrophy-Time for Common Nomenclature |
| Q37820101 | Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic |
| Q37896728 | Renal co-morbidity in patients with rheumatic diseases. |
| Q38673768 | Renal osteodystrophy in the obesity era: Is metabolic syndrome relevant? |
| Q38105272 | Renale osteodystrophie |
| Q86551198 | Reply to comment on "clinicians should be more prone to examine children with chronic kidney disease in terms of vitamin D deficiency" |
| Q59126536 | Rethinking Bone Disease in Kidney Disease |
| Q57492364 | Review on the Utility of Trabecular Bone Score, a Surrogate of Bone Micro-architecture, in the Chronic Kidney Disease Spectrum and in Kidney Transplant Recipients |
| Q36245734 | Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism |
| Q37108009 | Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease |
| Q37035197 | Risk factors for fracture in adult kidney transplant recipients |
| Q49557576 | Risk factors for heart valve calcification in chronic kidney disease |
| Q42685461 | Risk-factors for nodular hyperplasia of parathyroid glands in sHPT patients. |
| Q64970894 | Role of Albumin Assay on Calcium Levels and Prescription of Phosphate Binders in Chronic Hemodialysis Patients. |
| Q34639575 | Role of Residual Renal Function in Phosphate Control and Anemia Management in Chronic Hemodialysis Patients |
| Q33827652 | Role of TGF-β in a mouse model of high turnover renal osteodystrophy |
| Q40812164 | Role of Vitamin D deficiency in extraskeletal complications: predictor of health outcome or marker of health status? |
| Q26748967 | Role of Vitamin D in Cognitive Function in Chronic Kidney Disease |
| Q33655388 | Role of different imaging modalities of vascular calcification in predicting outcomes in chronic kidney disease. |
| Q28077133 | Role of low protein diet in management of different stages of chronic kidney disease - practical aspects |
| Q26765231 | Role of vitamin D in diabetes mellitus and chronic kidney disease |
| Q38069543 | Role of vitamin D in the development of insulin resistance and type 2 diabetes |
| Q33671574 | Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012. |
| Q33579748 | Routine mammography: an opportunity for the diagnosis of chronic degenerative diseases? A cross-sectional study. |
| Q92337205 | Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism |
| Q47114967 | Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease |
| Q33442494 | Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. |
| Q38034690 | Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies |
| Q39220825 | Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. |
| Q36740435 | Serum 25-hydroxyvitamin D as a predictor of hospitalization-free survival in predialysis and dialysis patients with chronic kidney disease: a single-center prospective observational analysis |
| Q35963073 | Serum Phosphorus Concentration and Coronary Artery Calcification in Subjects without Renal Dysfunction |
| Q84959556 | Serum adiponectin and bone mineral density in male hemodialysis patients |
| Q36466029 | Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea. |
| Q35023526 | Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population |
| Q56761596 | Serum phosphate level at initiation of dialysis is associated with all-cause mortality: a multicenter prospective cohort study |
| Q34406863 | Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis |
| Q36880126 | Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. |
| Q34695045 | Serum sclerostin is an independent predictor of mortality in hemodialysis patients |
| Q36977198 | Sevelamer Carbonate and Lanthanum Usage Evaluation and Cost Considerations at a Veteran's Affairs Medical Center |
| Q34505136 | Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials |
| Q38210438 | Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease |
| Q36443804 | Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. |
| Q38229798 | Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study |
| Q64064565 | Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature |
| Q44554035 | Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. |
| Q50701001 | Severe secondary hyperparathyroidism and panoramic radiography parameters. |
| Q55436115 | Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort. |
| Q98178864 | Short- and Long-term Effects of Dialysate Calcium Concentrations on Mineral and Bone Metabolism in Hemodialysis Patients: The K4 Study |
| Q44552901 | Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients |
| Q37212400 | Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients. |
| Q89280856 | Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease |
| Q38826040 | Skeletal implications and management of cystinosis: three case reports and literature review |
| Q90480569 | Small steps towards the potential of 'preventive' treatment of early phosphate loading in chronic kidney disease patients |
| Q34941418 | Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients |
| Q55406875 | Stabilization of serum alkaline phosphatase in hemodialysis patients by implementation of local chronic kidney disease-mineral bone disorder management strategy: A quality improvement study. |
| Q41936697 | Standards of clinical practice for renal pharmacists |
| Q92803503 | Strategies for Phosphate Control in Patients With CKD |
| Q64257622 | Study on the Prevalence of Vascular Calcification in Different Types of Arteries and Influencing Factors in Maintenance Peritoneal Dialysis Patients |
| Q37378259 | Subtotal parathyroidectomy for secondary renal hyperparathyroidism: a 20-year surgical outcome study |
| Q98178905 | Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study |
| Q38374335 | Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis |
| Q64079731 | Supplementary nutrients for prevention of vascular calcification in patients with chronic kidney disease |
| Q30316084 | Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons |
| Q40532142 | Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism |
| Q90324505 | Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease |
| Q34538433 | Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study |
| Q33983422 | Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States |
| Q92358412 | Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease |
| Q34500628 | Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation |
| Q35693460 | The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease |
| Q36155291 | The Association between Elevated Levels of Peripheral Serotonin and Its Metabolite - 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild Experimental Chronic Kidney Disease |
| Q60960439 | The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study |
| Q33702417 | The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients |
| Q33725069 | The DOPPS practice monitor for US dialysis care: potential impact of recent guidelines and regulatory changes on management of mineral and bone disorder among US hemodialysis patients |
| Q37454313 | The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system |
| Q64890295 | The Effect of Ketoanalogues on Chronic Kidney Disease Deterioration: A Meta-Analysis. |
| Q41261277 | The Effect of Parathyroidectomy on Risk of Hip Fracture in Secondary Hyperparathyroidism |
| Q42735739 | The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control |
| Q35576108 | The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial |
| Q38584122 | The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder |
| Q42697144 | The MIMIC Code Repository: enabling reproducibility in critical care research |
| Q41030014 | The Parathyroid Gland and Heart Disease |
| Q64120502 | The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease |
| Q57297242 | The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation |
| Q36022688 | The Survival of Roma Minority Patients on Chronic Hemodialysis Therapy - A Romanian Multicenter Survey |
| Q39185404 | The Use of a Multidimensional Measure of Dialysis Adequacy-Moving beyond Small Solute Kinetics |
| Q41602515 | The VITAH Trial-Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled Trial |
| Q34033076 | The VITAH trial VITamin D supplementation and cardiac Autonomic tone in Hemodialysis: a blinded, randomized controlled trial |
| Q33939290 | The association of chronic kidney disease complications by albuminuria and glomerular filtration rate: a cross-sectional analysis |
| Q49874313 | The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases |
| Q36318290 | The consequences of chronic kidney disease on bone metabolism and growth in children |
| Q36214854 | The demise of calcium-based phosphate binders-is this appropriate for children? |
| Q51244962 | The economic impact of acute kidney injury in England. |
| Q33649003 | The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease |
| Q42585296 | The effect of niacin on serum phosphorus levels in dialysis patients |
| Q34885173 | The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol |
| Q38100985 | The effect of vitamin D status on risk factors for cardiovascular disease |
| Q64095512 | The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism |
| Q58752367 | The effects of aerobic exercise on eGFR, blood pressure and VO2peak in patients with chronic kidney disease stages 3-4: A systematic review and meta-analysis |
| Q37734160 | The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study |
| Q51533235 | The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis |
| Q34293730 | The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis |
| Q37638164 | The growing problem of intradialytic hypertension |
| Q36391043 | The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study |
| Q92660950 | The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism |
| Q36613869 | The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection |
| Q93040283 | The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts |
| Q36577167 | The mechanism of vascular calcification - a systematic review. |
| Q36875566 | The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol |
| Q42600857 | The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification |
| Q38053246 | The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications |
| Q36906666 | The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores |
| Q35561373 | The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study |
| Q58784938 | The role of B-type natriuretic peptide in diagnosing acute decompensated heart failure in chronic kidney disease patients |
| Q40828040 | The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. |
| Q38836379 | The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives. |
| Q34376795 | The role of chelation in the treatment of other metal poisonings |
| Q38793054 | The role of phosphate in kidney disease |
| Q64081763 | The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease |
| Q30524695 | The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease |
| Q36337938 | The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study |
| Q37958665 | The surgical management of renal hyperparathyroidism |
| Q88104814 | The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease |
| Q57140321 | The unexpected presence of iron in bone biopsies of hemodialysis patients |
| Q39655039 | The use of vitamin D analogs is independently associated with the favorable renal prognosis in chronic kidney disease stages 4-5: the CKD-ROUTE study |
| Q50146635 | The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study |
| Q38150099 | Therapy for patients with CKD and low bone mineral density |
| Q60948025 | There Is No Impact of Diabetes on the Endothelial Function of Chronic Kidney Disease Patients |
| Q64236654 | Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study-A Comparison |
| Q34865383 | Tip-toeing toward the finish line |
| Q64977130 | Total Parathyroidectomy with Subcutaneous Parathyroid Forearm Autotransplantation in the Treatment of Secondary Hyperparathyroidism: A Single-Center Experience. |
| Q35838070 | Total parathyroidectomy with presternal intramuscular autotransplantation in renal patients: a prospective study of 66 patients. |
| Q83683568 | Total parathyroidectomy without autotransplantation in the surgical treatment of secondary hyperparathyroidism of chronic kidney disease |
| Q54889121 | Trabecular Bone Score and Incident Fragility Fracture Risk in Adults with Reduced Kidney Function. |
| Q41096407 | Trabecular bone score in kidney transplant recipients |
| Q37728330 | Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study |
| Q35026517 | Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrology |
| Q46631137 | Transplantation: An end to bone disease after renal transplantation? |
| Q39271483 | Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder |
| Q39374348 | Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide |
| Q42684253 | Treatment of severe metastatic calcification and calciphylaxis in dialysis patients |
| Q89157892 | Twenty-Four-Hour Urine Phosphorus as a Biomarker of Dietary Phosphorus Intake and Absorption in CKD: A Secondary Analysis from a Controlled Diet Balance Study |
| Q54912272 | Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. |
| Q49375971 | Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors |
| Q30378459 | Understanding the Full Spectrum of Organ Injury Following Intrapartum Asphyxia |
| Q38160473 | Update and critical appraisal of sevelamer in the management of chronic renal failure |
| Q39345412 | Uremic Toxicity and Bone in CKD. |
| Q42727513 | Uremic osteoporosis |
| Q38526304 | Use of magnesium as a drug in chronic kidney disease |
| Q37199788 | Use of nicotinamide to treat hyperphosphatemia in dialysis patients |
| Q64288909 | Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates |
| Q64956810 | Use of phosphate-binders and risk of infection-related and all-cause mortality in patients undergoing hemodialysis: The Q-Cohort Study. |
| Q35391160 | Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. |
| Q35891563 | Usefulness and feasibility of measuring ionized calcium in haemodialysis patients |
| Q34403806 | Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D |
| Q35452299 | Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease |
| Q52790284 | Value of Intraoperative Parathyroid Hormone Assay during Parathyroidectomy in Dialysis and Renal Transplant Patients with Secondary and Tertiary Hyperparathyroidism. |
| Q40138771 | Variability in measures of mineral metabolism in children on hemodialysis: impact on clinical decision-making |
| Q33944768 | Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis |
| Q42951724 | Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease |
| Q42282597 | Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients |
| Q37914009 | Vascular and valvular calcification in chronic peritoneal dialysis patients |
| Q59100578 | Vascular calcification and renal bone disorders |
| Q35735968 | Vascular calcification burden of Chinese patients with chronic kidney disease: methodology of a cohort study |
| Q39009566 | Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho |
| Q37195354 | Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication |
| Q34037021 | Vascular calcification in chronic kidney disease: role of disordered mineral metabolism |
| Q35278497 | Vascular calcification in patients with nondialysis CKD over 3 years |
| Q28071582 | Vascular calcification: When should we interfere in chronic kidney disease patients and how? |
| Q37763820 | Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis |
| Q91925269 | Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort |
| Q37387897 | Vitamin D (25(OH)D) in patients with chronic kidney disease stages 2-5 |
| Q98293290 | Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol |
| Q37615224 | Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching. |
| Q88648846 | Vitamin D and Calcimimetics in Cardiovascular Disease |
| Q37279081 | Vitamin D and Clinical Outcomes in Dialysis |
| Q38185029 | Vitamin D and UV exposure in chronic kidney disease |
| Q87419435 | Vitamin D and chronic kidney disease |
| Q37083785 | Vitamin D and immune function |
| Q37766789 | Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window |
| Q35856083 | Vitamin D deficiency in hemodialysis patients |
| Q33616582 | Vitamin D in Chronic Kidney Disease and Dialysis Patients |
| Q36956587 | Vitamin D in chronic kidney disease |
| Q38803449 | Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology |
| Q33703957 | Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease |
| Q37109797 | Vitamin D status in children with chronic kidney disease |
| Q39413414 | Vitamin D, a modulator of musculoskeletal health in chronic kidney disease. |
| Q93044600 | Vitamin D, bone alkaline phosphatase and parathyroid hormone in healthy subjects and haemodialysed patients from West Africa: impact of reference ranges and parathyroid hormone generation assays on the KDIGO guidelines |
| Q34621641 | Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. |
| Q39519961 | Vitamin D: something new under the sun. |
| Q35269754 | Vitamin d, and kidney disease |
| Q38161821 | What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy? |
| Q37231813 | What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? |
| Q37642219 | Whole blood versus serum ionized calcium concentrations in dialysis patients |
| Q55401771 | Why do we need regional chronic kidney disease-mineral bone disorders guidelines? |
| Q89167180 | Xerostomia, thirst, sodium gradient and inter-dialytic weight gain in hemodialysis diabetic vs. non-diabetic patients |
| Q90155675 | [Treatment of rheumatic disease with renal insufficiency] |